TrialLeukemia2017

Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma.

J Martinez-Lopez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.